三阴性乳腺癌细胞生长增殖的不同调节机制研究进展  

Research progress on different regulatory mechanisms of triple-negative breast cancer

作　　者：黄亚楠[1] 秦嘉萍 刘嫱[1] 符健[1] Huang Yanan;Qin Jiaping;Liu Qiang;Fu Jian(Department of Pharmacology,Hainan Medical University,Haikou 571199,China)

机构地区：[1]海南医学院药理学教研室,海南571199

出　　处：《中华内分泌外科杂志》2023年第5期635-637,共3页Chinese Journal of Endocrine Surgery

基　　金：海南省高校研究重点项目(Hnky2019ZD-26)。

摘　　要：根据生物学功能的不同,乳腺癌可分为三阴性乳腺癌(triple negative breast cancer,TNBC)和非三阴性乳腺癌,前者细胞的增殖侵袭能力更强、转移更快,其免疫组织指标雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和人表皮生长因子2受体(human epidermal growth factor receptor,HER2)均为阴性。外科手术和放射疗法是TNBC的传统疗法,但这些疗法副作用多且预后性差。为更好地预防TNBC的扩散和治疗,研究其癌细胞的生长、增殖和凋亡机制显得尤为重要。近年研究得知多种信号通路、lncRNA、miRNA都影响着TNBC的生长过程。本文综述国内外对TNBC细胞增殖凋亡过程中相关调节机制的研究,旨在阐明乳腺癌细胞增殖和凋亡途径的重要性,为TNBC靶向性治疗的药品研发提供新的思路。According to different biological functions,breast cancer can be divided into triple-negative breast cancer and non-triple-negative breast cancer.The former has stronger proliferation and invasion ability and faster metastasis.Its immune tissue indicators are estrogen receptor(estrogen receptor,ER)and progesterone receptor.Both the body(progesterone receptor,PR)and human epidermal growth factor 2 receptor(human epidermal growthFactor receptor,HER2)are negative.Surgery and radiotherapy are traditional therapies for TNBC,but these therapies have many side effects and poor prognosis.In order to better prevent the spread and treatment of TNBC,it is particularly important to study the growth,proliferation and apoptosis mechanisms of cancer cells.In recent years,studies have shown that a variety of signaling pathways,lncRNA,and miRNA all affect the growth process of TNBC.In recent years,studies have shown that a variety of signaling pathways,lncRNA,and miRNA all affect the growth process of TNBC.This article reviews domestic and foreign studies on the relevant regulatory mechanisms of TNBC cell proliferation and apoptosis,aiming to clarify the importance of breast cancer cell proliferation and apoptosis pathways,and provide new ideas for drug development for TNBC targeted therapy.

关 键 词：三阴性乳腺癌 PI3K/AKT/mTOR通路 lncRNA MIRNA 增殖凋亡 

分 类 号：R737.9[医药卫生—肿瘤]